<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-053092</identifier>
<setSpec>0210-0010</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Statins and cerebrovascular disease: new perspectives in stroke prevention</dc:title>
<dc:description xml:lang="en">Introduction and development. The role played by statins in the prevention of strokes has been subject to controversy        for a long time, especially because no clear correlation between levels of cholesterol in serum and strokes has yet been        established. Nevertheless, a number of randomised trials with statins and several meta-analyses that were carried out later        have proved that statins lower the incidence of all kinds of strokes, with a 21% reduction in the relative risk. It has also been        shown that this effect is essentially due to the degree to which LDL cholesterol (cholesterol linked to low-density lipoproteins)        is reduced, which has a lowering effect on lipid levels. It has also been shown that statins have others beneficial effects apart        from reducing cholesterol levels and that these may be independent of the subject&#146;s basal lipid levels. We are referring to the        so-called pleiotropic effects, which include stabilisation of the atherosclerotic plaque, an antiinflammatory effect, an antithrombotic        effect and enhanced vasomotor reactivity. Conclusion. The recent appearance of the results of the SPARCL (Stroke        Prevention by Aggressive Reduction in Cholesterol Levels) study and the guidelines published by the American Heart        Association and the Spanish Neurology Society, which grant statins a leading role in stroke prevention, both open up new        horizons for the use of statins in cerebrovascular pathologies</dc:description>
<dc:creator>Fernández-Moreno, M. C</dc:creator>
<dc:creator>Jiménez-Hernández, M. D</dc:creator>
<dc:creator>López-Chozas, J. M</dc:creator>
<dc:creator>Castilla-Guerra, L</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Introducción y desarrollo. El papel de las estatinas en la prevención del ictus ha sido durante mucho tiempo tema de        controversia, sobre todo porque la correlación entre los niveles séricos de colesterol e ictus no se ha establecido con claridad.        No obstante, numerosos ensayos aleatorizados con estatinas y varios metaanálisis posteriores han demostrado que las estatinas        disminuyen la incidencia de ictus de cualquier tipo, con una reducción de riesgo relativo del 21%, y este efecto se debe fundamentalmente        al grado de reducción del colesterol LDL (colesterol ligado a lipoproteínas de baja densidad), con efecto hipolipemiante.        También se ha demostrado que los beneficios de las estatinas van más allá de la reducción de los niveles de colesterol        y que éstos pueden ser independientes de los niveles basales de lípidos del sujeto. Son los denominados efectos pleiotrópicos,        entre los cuales se incluyen la estabilización de la placa aterosclerótica, el efecto antiinflamatorio, el efecto antitrombótico        y la mejora de la reactividad vasomotora. Conclusión. La reciente aparición de los resultados del estudio SPARCL (Stroke        Prevention by Aggressive Reduction in Cholesterol Levels), junto con la publicación de las guías de la American Heart Association        y de la Sociedad Española de Neurología, que otorgan a las estatinas un papel principal en la prevención del ictus,        abren nuevas perspectivas para el uso de las estatinas en la patología vasculocerebral</dc:description>
<dc:source>Rev Neurol;44(2): 95-100, feb. 2007. graf</dc:source>
<dc:identifier>ibc-053092</dc:identifier>
<dc:title xml:lang="es">Estatinas y enfermedad cerebrovascular: nuevas perspectivas en la prevención del ictus</dc:title>
<dc:subject>^d29646</dc:subject>
<dc:subject>^d33014^s22078</dc:subject>
<dc:subject>^d33014^s22073</dc:subject>
<dc:subject>^d5478^s22073</dc:subject>
<dc:subject>^d2582^s22036</dc:subject>
<dc:subject>^d22431</dc:subject>
<dc:subject>^d29640</dc:subject>
<dc:subject>^d5478^s22078</dc:subject>
<dc:subject>^d30291</dc:subject>
<dc:subject>^d27938^s22073</dc:subject>
<dc:subject>^d1166^s22054</dc:subject>
<dc:subject>^d34247^s22054</dc:subject>
<dc:subject>^d27938^s22078</dc:subject>
<dc:subject>^d7117^s22057</dc:subject>
<dc:subject>^d7117^s22054</dc:subject>
<dc:subject>^d8252^s22062</dc:subject>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d33014^s22020</dc:subject>
<dc:subject>^d33014^s22000</dc:subject>
<dc:subject>^d28567</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d5478^s22020</dc:subject>
<dc:subject>^d29770</dc:subject>
<dc:subject>^d5478^s22000</dc:subject>
<dc:subject>^d27938^s22020</dc:subject>
<dc:subject>^d27938^s22000</dc:subject>
<dc:subject>^d7117^s22062</dc:subject>
<dc:type>article</dc:type>
<dc:date>200702</dc:date>
</metadata>
</record>
</ibecs-document>
